Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms-Reference-Cited by-同舟云学术

Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms

Published:2019-11-25 Issue:22 Volume:3 Page:3700-3708
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Hong Junshik¹^ORCID,Lee Ju Hyun²,Byun Ja Min¹,Lee Ji Yun²,Koh Youngil¹,Shin Dong-Yeop¹,Lee Jeong-Ok²,Hwang Sang Mee³^ORCID,Choi Hyoung Soo⁴^ORCID,Kim Inho¹,Yoon Sung-Soo¹^ORCID,Bang Soo-Mee²

Affiliation:

1. Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea; and

2. Department of Internal Medicine,

3. Department of Laboratory Medicine, and

4. Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam National University College of Medicine, Seongnam, South Korea

Abstract

Key Points South Korean MPN patients had a significantly higher risk of developing second primary solid tumors than that of the general population. Patients with SMF had an overall survival comparable to those with PMF with less risk of developing SAML.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/3/22/3700/1543944/advancesadv2019000655.pdf

Reference34 articles.

1. Myeloproliferative neoplasms: a contemporary review;Tefferi;JAMA Oncol,2015

2. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management;Tefferi;Am J Hematol,2017

3. Recent advances in the diagnosis and management of primary myelofibrosis;Takenaka;Korean J Intern Med (Korean Assoc Intern Med),2018

4. A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database;Brunner;Leuk Lymphoma,2016

5. Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients;Landtblom;Leukemia,2018

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment with ropeginterferon alfa-2b in patients with hydroxyurea resistant or intolerant polycythemia vera in South Korea: one-year results from a phase 2 study;Blood Research;2024-07-09

2. Risk of thrombosis, hemorrhage and leukemic transformation in patients with myeloproliferative neoplasms: A nationwide longitudinal cohort study;Thrombosis Research;2024-04

3. Exposure–efficacy and exposure–safety analyses of ropeginterferon alfa‐2b treatment in patients with polycythaemia vera;British Journal of Clinical Pharmacology;2024-03-19

4. Ph-Negative Chronic Myeloproliferative Neoplasms;Comprehensive Hematology and Stem Cell Research;2024

5. Incidental abdominal computed tomography findings in patients newly diagnosed with Philadelphia-negative myeloproliferative neoplasm;Blood Research;2023-10-19